| Literature DB >> 32304665 |
Katherine Minjee Chung1, Jaffarguriqbal Singh2, Lauren Lawres2, Kimberly Judith Dorans1, Cathy Garcia2, Daniel B Burkhardt3, Rebecca Robbins1, Arjun Bhutkar1, Rebecca Cardone4, Xiaojian Zhao4, Ana Babic5, Sara A Vayrynen5, Andressa Dias Costa5, Jonathan A Nowak6, Daniel T Chang7, Richard F Dunne8, Aram F Hezel8, Albert C Koong9, Joshua J Wilhelm10, Melena D Bellin11, Vibe Nylander12, Anna L Gloyn13, Mark I McCarthy13, Richard G Kibbey4, Smita Krishnaswamy3, Brian M Wolpin5, Tyler Jacks14, Charles S Fuchs15, Mandar Deepak Muzumdar16.
Abstract
Obesity is a major modifiable risk factor for pancreatic ductal adenocarcinoma (PDAC), yet how and when obesity contributes to PDAC progression is not well understood. Leveraging an autochthonous mouse model, we demonstrate a causal and reversible role for obesity in early PDAC progression, showing that obesity markedly enhances tumorigenesis, while genetic or dietary induction of weight loss intercepts cancer development. Molecular analyses of human and murine samples define microenvironmental consequences of obesity that foster tumorigenesis rather than new driver gene mutations, including significant pancreatic islet cell adaptation in obesity-associated tumors. Specifically, we identify aberrant beta cell expression of the peptide hormone cholecystokinin (Cck) in response to obesity and show that islet Cck promotes oncogenic Kras-driven pancreatic ductal tumorigenesis. Our studies argue that PDAC progression is driven by local obesity-associated changes in the tumor microenvironment and implicate endocrine-exocrine signaling beyond insulin in PDAC development.Entities:
Keywords: beta cells; cholecystokinin; genetically engineered mouse models; leptin; obesity; pancreatic cancer; pancreatic islets; tumor microenvironment
Mesh:
Year: 2020 PMID: 32304665 PMCID: PMC7266008 DOI: 10.1016/j.cell.2020.03.062
Source DB: PubMed Journal: Cell ISSN: 0092-8674 Impact factor: 41.582